<DOC>
	<DOC>NCT00938496</DOC>
	<brief_summary>This is a prospective, open label NIS, which is to assess the efficacy of Zoladex in adjuvant setting after operation in moderate to severe endometriosis patients.</brief_summary>
	<brief_title>Non-Interventional Study of Zoladex in Endometriosis</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>Advanced endometriosis confirmed histologically (rAFS score IIIIV) with conservative laparoscopy or laparotomy. Patient who has the indication of Zoladex and has been prescribed Zoladex according to physician's judgement, irrespective of the inclusion in the study. Patient has been already prescribed Zoladex within 1 month after operation. Have used hormone treatment prior to 3 months of recruitment. Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site). Previous enrolment in the present study.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>